INTRODUCTION
============

In recent reports, the prevalence of male infertility (which can be defined as infertility experienced for at least 12 months) varies from 9% to 15.8% of the general population \[[@B1]\]. Many conventional therapies are available to treat male infertility, but their efficacy is unclear \[[@B2][@B3]\]. People with infertility problems often seek complementary and alternative medicine \[[@B4]\]. Several studies have shown that many sufferers have used some form of herbal medicine, such as dang gui, maca, or ginseng, in order to try to improve their fertility, libido, and sexual performance \[[@B4][@B5][@B6][@B7][@B8][@B9][@B10][@B11]\]. Ginseng is the root of the Panax plant. It can be administered in various forms, including tablets, liquid extracts, tinctures, powdered roots, sliced roots and teas. Ginseng has been found to have several classes of chemical constituents, including ginsenosides, polysaccharides, alkaloids, glucosides, and phenolic acid \[[@B12][@B13]\]. Many studies have demonstrated the bioactivity of ginseng, namely its antioxidant, anti-inflammatory, anti-aging, anti-diabetic, anti-cancer, neuroregulation, lipid regulation and antithrombotic properties, as well as its pharmacokinetics \[[@B13][@B14]\]. As such, ginseng has been utilized as an 'adaptogen for promoting resistance to external and internal stresses or stimuli and improving both physical and mental faculties' \[[@B14]\].

Several preclinical studies have reported that ginseng promotes spermatogenesis, as well as improving testicular problems, sperm quality, and sperm mobility, due to be a cyclic adenosine monophosphate-responsive element modulator \[[@B15][@B16][@B17][@B18][@B19][@B20]\]. Recent reviews summarize that ginsenosides---the predominant active compounds of ginseng---may affect estrogen and androgen activity, and act as an aphrodisiac \[[@B21][@B22]\]. Ginseng polysaccharides may modulate estrogen receptors and the beneficial effects on estrogen-induced physiological states. In addition, they play a role in maintaining healthy levels of steroid hormone receptors, ensuring the proper functioning of androgen hormones in turn \[[@B22]\]. However, the exact mechanism through which ginseng functions as an enhancer of sperm quality has not been studied in sufficient detail to date; there has been no systematic review of the role of ginseng in improving semen quality parameters. The objective of this study, therefore, is to assess current evidence that ginseng can improve sperm quality.

MATERIALS AND METHODS
=====================

1. Study registration and published protocol
--------------------------------------------

We registered the following protocol on PROSPERO: CRD42017078797 (<http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017078797>). The full protocol was published as recommended, and the methods described in this systematic review are the same as those published \[[@B23]\].

2. Ethical statement
--------------------

No ethical approval was required for this manuscript as this study did not involve human subjects or laboratory animals.

3. Inclusion and exclusion criteria
-----------------------------------

### 1) Types of study

We included all prospective randomized clinical trials (RCTs), controlled clinical trials (CCTs), and uncontrolled observational studies (UOS) available across the twelve databases selected. We excluded case studies, case series, and retrospective clinical studies.

### 2) Types of participant

We included healthy men, or men with subfertility or infertility, regardless of age.

### 3) Types of intervention

We included studies involving any type of ginseng (used alone or as a co-intervention with conventional medicines), regardless of its origin, age, or processing status, or the dose used. The inclusion criteria for the controls were no treatment, placebos, or conventional medicines.

### 4) Types of outcome measure

\(1\) Primary outcomes: sperm motility and sperm concentration

\(2\) Secondary outcomes: sperm morphology, sperm count, semen volume, and adverse events (AEs)

4. Search methods
-----------------

### 1) Searched electronic databases

We searched twelve databases, without placing limits on the language of publication or on publication status, from the databases\' inception to 1st December, 2019. The databases included were PubMed, the Cochrane Library, EMBASE, AMED, five Korean medical databases (the Research Information Service System \[RISS\], the Korean Studies Information Service System \[KISS\], KoreaMed, DBpia, OASIS), and three Chinese medical databases (China National Knowledge Infrastructure \[CNKI\], the Wanfang Database, and the Chinese Scientific Journals Database \[VIP\]).

With a view to including ongoing studies, we searched the following databases: World Health Organization International Clinical Trials Registry Platform (ICTRP) (<http://apps.who.int/trialsearch/>); Chinese Clinical Trial Registry ([www.chictr.org](http://www.chictr.org)); ISRCTN ([www.controlledtrials.com/isrctn/](http://www.controlledtrials.com/isrctn/)); National Institutes of Health Clinical Trials Database ([www.clinicaltrials.gov](https://www.clinicaltrials.gov/)); Clinical Research Information Service (CRiS) of the Republic of Korea (<https://cris.nih.go.kr/cris/en/>).

### 2) Other sources

We also searched 'The Journal of Ginseng Research' and 'Proceedings of the Ginseng Society Conference' manually. Then, we reviewed all the studies included again in order to select those potentially suitable for inclusion in our study.

### 3) Search strategy

The search terms we utilized were 'Panax ginseng OR ginseng' and 'semen OR sperm OR hyposperm OR subfertility'. The search strategy involved using a mixture of free text and thesaurus terms in English, Korean, and Chinese.

5. Selection of studies and data extraction
-------------------------------------------

Two reviewers (HWL, KJK) selected potentially eligible articles by reading through titles and abstracts. These reviewers examined hard copies of the publications in order to determine their suitability. Any disagreements were resolved through discussion, and where necessary, in consultation with a third reviewer (MSL).

Two reviewers (HWL, KJK) extracted data from the studies included. Information that was excluded was as follows: the characteristics of subjects, the types of ginseng therapy used, the outcomes, and the results. We resolved disagreements through discussion and in consultation with the third author (MSL), who acted as an arbiter.

6. Assessment of risk of bias
-----------------------------

Two reviewers (HWL, MSL) independently evaluated the risk of bias (ROB) in the studies included by following the guidelines given in the "Cochrane Handbook of Systematic Reviews of Interventions (*i.e.*, sequence generation, allocation concealment, blinding, incomplete outcome data, and selective outcome reporting)" \[[@B24]\]. Although ROB tools generally assess the ROBs in RCTs, we also used this method to examine CCTs and UOSs for bias.

7. Data synthesis
-----------------

We presented dichotomous data in terms of risk ratios, with 95% confidence intervals (CIs). We used the mean difference with 95% CIs for continuous data, and the standard mean difference for outcome variables with different scales. We were unable to conduct a meta-analysis due to the small number of studies included.

RESULTS
=======

1. Study description
--------------------

Of 219 eligible hits, 136 studies were excluded following screening the abstracts and titles. After assessing 19 full-text articles, 14 studies were excluded for several reasons ([Fig. 1](#F1){ref-type="fig"}). Finally, five studies met our inclusion criteria \[[@B25][@B26][@B27][@B28][@B29]\]. We summarize the key data from these studies in [Table 1](#T1){ref-type="table"}. Two of the studies were RCTs \[[@B25][@B26]\], one was a CCT \[[@B27]\], and two were UOSs \[[@B28][@B29]\]. Of the five studies, one trial was performed in the USA \[[@B26]\], three were performed in Korea \[[@B25][@B27][@B28]\], and one was conducted in Italy \[[@B29]\]. All the studies used oral ginseng, and the daily dosages were 1.5--4 g of ginseng for 10 days to 12 weeks. One study included healthy men \[[@B26]\], two were undertaken with infertile men \[[@B25][@B29]\], and the other two studies included both infertile and healthy men \[[@B27][@B28]\].

2. Risk of bias
---------------

Only one RCT \[[@B25]\] noted the use of random sequence generation methods; the other RCT \[[@B26]\] failed to do so ([Fig. 2](#F2){ref-type="fig"}). In the former RCT, both the patients and practitioner were blinded \[[@B25]\], while the latter was an open-labeled RCT \[[@B26]\]. The CCT was published as an abstract only, and it noted the use of a double-blinded multi-center trial \[[@B27]\]. The other two studies were UOSs, with high ROBs \[[@B28][@B29]\].

3. Outcomes
-----------

### 1) Infertile men

One RCT tested the efficacy of Korean red ginseng (KRG) alone and KRG plus varicocelectomy in improving sperm quality parameters, when compared with the use of a placebo or a placebo plus varicocelectomy in 80 infertile men \[[@B25]\]. This trial\'s results indicated the beneficial effects of using KRG alone, as sperm concentration, morphology, viability, and motility were found to be improved with KRG, when the results were compared with those for the placebo group. Additionally, the use of KRG plus varicocelectomy was shown to have positive effects on sperm morphology and viability, when compared with the use of a placebo plus varicocelectomy. The CCT showed that mountain ginseng has significant positive effects on semen volume, sperm concentration, and morphology but not on sperm motility, when compared with pre-treatment scores \[[@B27]\]. On the other hand, the two UOSs failed to show that ginseng has any significant impact on semen parameters in infertile men \[[@B27][@B28]\].

### 2) Healthy volunteers

One of the RCTs included investigated the efficacy of a ginseng mixture in improving semen quality, when compared with the results for valerian tablets in healthy men. The study showed that the ginseng mixture had positive effects on semen volume, concentration, motile sperm count, and total sperm count, all of which were equivalent to the results obtained by utilizing valerian tablets \[[@B26]\]. The CCT, however, did not find that there was a significant improvement in semen quality parameters after taking ginseng, when compared with the use of a placebo \[[@B27]\]. Additionally, the two UOSs indicated that ginseng does not have significant effects on semen quality, when compared with baseline values \[[@B28][@B29]\].

### 3) Adverse events

Although all of the five studies investigated AEs, two did not report on them. Two of the studies found that there were no AEs \[[@B26][@B27]\], while another stated that elevated temperature, headache, and indigestion were reported \[[@B28]\].

DISCUSSION
==========

Our results show that a small body of research exists on the effects of ginseng on semen quality parameters. One RCT that we investigated demonstrated the efficacy of KRG in improving semen quality parameters in infertile men \[[@B25]\], although another RCT that we examined failed to find any improvement in these parameters in healthy men \[[@B26]\]. The remaining three studies, all of which had high ROBs, also failed to show that KRG, mountain ginseng, and white ginseng respectively have positive effects on these parameters in either infertile or healthy men \[[@B27][@B28][@B29]\]. It should be acknowledged that the collective evidence was limited; the total number of studies and the total sample size were both too small for definite conclusions to be drawn.

One of the studies included was published as an abstract only and had not been through a rigorous peer review process, meaning that the study could not be evaluated to any great extent \[[@B27]\]. Two of the studies were UOSs with a high risk of potential bias; for example, the treatment effects were overstated in places \[[@B28][@B29]\]. Furthermore, all of the studies included had small sample sizes (ranging between 14 and 80), and were prone to type II errors.

One common concern surrounding the use of ginseng it is that it may bring about more AEs than conventional therapies. Two trials found that there were no AEs \[[@B26][@B27]\], while one study reported that were no severe AEs \[[@B28]\]. As such, the potential for ginseng use to lead to AEs needs to be investigated further in future studies.

The doses of ginseng reported in the studies included in our analysis were 3 g/d for 10 days and 4 g/d for 12 weeks. No detailed information was provided for mountain ginseng. The dose of KRG was 1.5 g/d for 12 weeks and 2.4 g/d for 8 weeks. Hence, all the RCTs in our review reported various doses of ginseng. It is clear that further study of clinical trials comparing the dosage, duration, and type of ginseng are required.

Assuming that ginseng is beneficial for improving sperm quality, its possible mechanisms of action may be of interest. As in the case of all herbal extracts, ginseng preparations are complex mixtures of multiple pharmacologically active ingredients. The most important and best researched of the active ingredients in ginseng are the ginsenosides, a diverse group of saponins that are structurally similar to steroid hormones. Thus, it was speculated that the effects of ginsenosides on sperm formation are the result of activation of steroid hormone receptors \[[@B22][@B30]\]. It was also suggested that the effects of ginseng may extend to other biochemical variables, including hormones, oxidative biomarkers, reactive oxygen species, and apoptosis \[[@B20][@B30]\]. In this review, three of the included studies assessed the biochemical parameters, including hormones \[[@B25][@B28][@B29]\]. However, the results were not consistent, and several limitations prevented their confirmation. Therefore, the mechanisms of action of ginseng are diverse, complex and often somewhat unclear. Further basic research is needed to fully understand these mechanisms.

This review also has several limitations. Although we conducted a comprehensive search, we cannot completely rule out the possibility that we may have overlooked other relevant articles. In addition, many studies on ginseng have received support from manufacturers of ginseng products, which could cause potential conflicts of interest and intrinsic biases. For instance, one of the studies included in this review received ginseng from an associated company. Moreover, the quality of the reporting in the studies examined was poor, lacking detail. It is very important to follow rigorous methods and CONSORT reporting guidelines for improving the evidence levels. Further limitations include a lack of methodological rigor in the primary data examined and the fact that most of the studies failed to minimize bias.

CONCLUSIONS
===========

Our results suggest that there is limited evidence that ginseng can improve semen quality parameters. However, given the overall ROB, the small number of studies included, and the total sample size, we cannot draw firm conclusions. This study contends, therefore, that more academically rigorous studies are required in order to examine this subject further.

Hye Won Lee and Myeong Soo Lee were supported by Korea Institute of Oriental Medicine (K18043 and KSN2013210), Korea.

**Conflict of Interest:** Dr. Myeong Soo Lee is one of editorial board of Journal of Ginseng Research, but it made no influence on this work in relation with topic. Other authors have nothing to disclose.

**Author Contribution:** **Conceptualization:** HWL, MSL.**Data curation:** HWL, MSL.**Formal analysis:** HWL, MSL.**Funding acquisition:** HWL, MSL.**Investigation:** HWL, MSL.**Methodology:** HWL, MSL.**Project administration:** HWL, MSL.**Resources:** HWL, MSL.**Software:** HWL, MSL.**Supervision:** HWL, MSL.**Validation:** KJK, MSL.**Visualization:** HWL, MSL.**Writing --- original draft:** HWL, KJK.**Writing --- review & editing:** HWL, MSL.
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###### Summary of clinical trials focusing on the effect of ginseng on semen quality parameters

![](wjmh-38-377-i001)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author (year)/location          Sample size and condition                                                                                            Intervention (regimen)                                                                        Control intervention (regimen)                                                     Main outcome measures        Results                                                                                  Adverse effects
  ------------------------------------- -------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ---------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------
  Park (2016) \[[@B25]\]/Korea          RCT\                                                                                                                 \(A\) KRG (500 mg/capsule, 3 capsules/d, total 1.5 g/d for 12 wk, n=20)\                      \(C\) Placebo (n=20)\                                                              \(1\) Sperm concentration\   1\) A *vs.* C: p=0.009, 0.86 (0.21--1.51); B *vs.* D: NS, 0.15 (-0.49--0.80)\            n.r.\
                                        80 infertile men\                                                                                                    (B) KRG (500 mg/capsule, 3 capsules/d, total 1.5 g/d for 12 wk, n=20), plus varicocelectomy   (D) Placebo (n=20), plus varicocelectomy                                           (2) Sperm morphology\        (2) A *vs.* C: p\<0.001, 5.7 (4.24--7.15); B *vs.* D: p\<0.001, 2.15 (1.32--2.98)\       KGC supported (ginseng)
                                        25--45 y                                                                                                                                                                                                                                                                                              (3) Semen viability\         (3) A *vs.* C: p\<0.001, 3.23 (2.26--4.20); B *vs.* D: p=0.002, 1.08 (0.39--1.78)\       
                                                                                                                                                                                                                                                                                                                                              (4) Sperm motility           (4) A *vs.* C: p\<0.001, 2.25 (1.45--3.06); B *vs.* D: NS, 0.59 (-0.07--1.26)            

  Mkrtchyan (2005) \[[@B26]\]/Armenia   RCT\                                                                                                                 \(A\) Ginseng mixture (ginsenoside, 85.7 m/d=3 g of dry ginseng/ginseng for 10 d, n=5)        \(B\) Valerian tablet (1.28 g/d for 10 d, n=5)\                                    \(1\) Semen volume\          \(1\) NS, -0.13 (-1.37--1.11)\                                                           None
                                        14 healthy men\                                                                                                                                                                                                    (C) Herbal mixtures (company commercial product, 60 mg/d, for 10 d, n=5)^a^\       (2) Sperm concentration\     (2) NS, -0.52 (-1.66--0.62)\                                                             
                                        21--31 y                                                                                                                                                                                                           (D) Herbal mixtures (company commercial product, 120 mg/d, for 10 days, n=5)^a^\   (3) Motile sperm count\      (3) NS, -0.08 (-1.32--1.16)\                                                             
                                                                                                                                                                                                                                                           (E) Herbal mixtures (company commercial product, 180 mg/d, for 10 d, n=6)^a^       (4) Total sperm count        (4) NS, -0.11 (-1.35--1.13)                                                              

  Lee (2006) \[[@B27]\]/Korea           CCT\                                                                                                                 \(A\) Mountain ginseng (n.r. in details, n=21)                                                \(B\) Placebo (n=12)\                                                              \(1\) Semen volume\          (1)--(3) p\<0.05 for A but NS for B and C (intergroup analysis)\                         None\
                                        43 participants (33 infertile men; 10 healthy men)\                                                                                                                                                                (C) Health control (n=12)                                                          (2) Sperm concentration\     (4) NS for all groups (intergroup analysis)                                              Abstract only
                                        n.r.                                                                                                                                                                                                                                                                                                  (3) Sperm morphology\                                                                                                 
                                                                                                                                                                                                                                                                                                                                              (4) Sperm motility                                                                                                    

  Kim (2002) \[[@B28]\]/Korea           UOS (case control)\                                                                                                  \(A\) KRG (300 mg/capsule, 8 capsules/d, total 2.4 g for 8 wk, n=37)                          N/A                                                                                \(1\) Semen volume\          (1)--(4) NS for both infertility and healthy participants                                Heat (8), headache (1), indigestion (1)\
                                        Total 37 participants (25 infertile men; 12 healthy men)\                                                                                                                                                                                                                                             (2) Sperm concentration\                                                                                              26 participants were analyzed (18 infertility and 8 healthy men)
                                        34.3 y                                                                                                                                                                                                                                                                                                (3) Sperm morphology\                                                                                                 
                                                                                                                                                                                                                                                                                                                                              (4) Sperm motility                                                                                                    

  Salvati (1996) \[[@B29]\]/Italy       UOS (case control)\                                                                                                  \(A\) Panax ginseng (extract, 4 g/d for 3 mo, n=66)                                           N/A                                                                                \(1\) Sperm counts\          (1), (2) Increased compared with baseline but n.r. in statistically significant levels   n.r.
                                        Total 66 participants (30 oligoasthenospermia; 16 oligoasthenospermia with idiopathic varicocele; 20 healthy men)\                                                                                                                                                                                    (2) Sperm motility                                                                                                    
                                        n.r.                                                                                                                                                                                                                                                                                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RCT: randomized clinical trial, CCT: controlled clinical trial, UOS: uncontrolled observational study, n.r.: not reported, KRG: Korean red ginseng, NA: not available, NS: not significant, KGC: Korean Ginseng Corporation.

^a^These parts were not considered in the analysis.
